Genoplex

Recognizing the need for a more specialized approach, Chris engaged BitLab and CTO Shoukri Kattan to address these challenges and guide Genoplex from idea to product launch. Team and code-base assessment was offered. Upon close audit, it was clear that both the team and the code had to be replaced to produce the results the Founder was looking for.

‍

1) Fractional CTO Leadership and Technical Strategy:

• BitLab brought in experienced technical leadership to provide strategic guidance and ensure that business goals aligned with the development roadmap.
• The team immediately recognized the importance of healthcare-specific regulations and took steps to integrate compliance measures from the start.
• A patent was filed jointly between Chris Leidli and Shoukri Kattan, reflecting the innovation brought to the platform.

2) Rapid and Effective Software Development:

• Within 90 days, BitLab successfully transitioned the project from its stalled state to a functioning prototype.
• This included both front-end and back-end development using technologies like MedStack and Azure Cloud, while ensuring HIPAA compliance and best practices in data privacy.

3) Customer-Centric Design:

• BitLab implemented a user-friendly interface for healthcare providers and patients alike, allowing both parties to make referrals or find treatment centers with ease.
• Input from healthcare advisory boards helped refine user flows and improve the platform’s overall functionality.

4) Scalable Infrastructure for Future Growth:

• A robust, scalable architecture was developed to support future integrations and expand globally. This foundation allows Genoplex to adapt to evolving market needs while ensuring compliance with healthcare regulations.

5) Assisted with investor pitches, as well as pre-sale and sales activities.

• BitLab supported Genoplex with investor pitches, helping to secure interest from global pharmaceutical companies. This was pivotal in preparing the platform for global rollout.

After partnering with BitLab, Genoplex achieved significant milestones that positioned them for future success:

‍

1) Accelerated Prototype Development:

• Within just 90 days of engagement, Genoplex went from a stalled project to launching a functional prototype, allowing them to begin market testing and secure customer interest.

2) Global Pharmaceutical Interest:

• With a strong platform now in place, Genoplex has attracted interest from major global pharmaceutical companies eager to collaborate and expand the platform’s reach into international markets.

3) Improved Efficiency and Project Management:

• BitLab’s leadership ensured that development progressed smoothly and efficiently, avoiding the delays and miscommunication that plagued previous attempts. This allowed Genoplex to deliver results on time and within budget.

4) Customer Validation and Market Fit:

• Genoplex’s platform quickly gained traction, with healthcare providers and patients alike finding value in its ability to streamline referrals and improve access to advanced therapies.

5) Patent filed jointly between Genoplex CEO and Shoukri (Head CTO), which offered several key benefits:

• Intellectual Property Protection: The patent safeguards the platform’s unique features and functionality.
• Market Advantage: By securing the patent, Genoplex gains a competitive edge, positioning itself as a leader in healthcare technology.
• Broad Applicability: The platform’s architecture can be adapted across various industries, opening new revenue streams.
• Increased Valuation: The patent adds value to the company, increasing its attractiveness to investors and strategic partners.
• Revenue Generation: The patent can generate additional revenue streams through licensing agreements or partnerships with other companies looking to use the technology.

Shoukri continues to assist the project with additional development and technical leadership as the CTO of Genoplex.

‍